help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-0285
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/10/5723    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leboulleux, S.
Right arrow Articles by Schlumberger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leboulleux, S.
Right arrow Articles by Schlumberger, M.
Related Collections
Right arrow Thyroid
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 10 5723-5729
Copyright © 2005 by The Endocrine Society

Prognostic Factors for Persistent or Recurrent Disease of Papillary Thyroid Carcinoma with Neck Lymph Node Metastases and/or Tumor Extension beyond the Thyroid Capsule at Initial Diagnosis

Sophie Leboulleux, Carole Rubino, Eric Baudin, Bernard Caillou, Dana M. Hartl, Jean-Michel Bidart, Jean-Paul Travagli and Martin Schlumberger

Departments of Nuclear Medicine and Endocrine Tumors (S.L., E.B., M.S.), Institut National de la Santé et de la Recherche Médicale U605 (C.R.), Pathology (B.C.), Surgical Oncology (J.-P.T., D.M.H.), and Clinical Biology (J.-M.B.), Institut Gustave Roussy, 94805 Villejuif Cédex, France

Address all correspondence and requests for reprints to: Martin Schlumberger, M.D., Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Rue Camille Desmoulins, 94805 Villejuif Cedex, France. E-mail:schlumbg{at}igr.fr.

Context: Reliable prognostic factors are needed in papillary thyroid cancer patients to adapt initial therapy and follow-up schemes to the risks of persistent and recurrent disease.

Objective and Settings: To evaluate the respective prognostic impact of the extent of lymph node (LN) involvement and tumor extension beyond the thyroid capsule, we studied a group of 148 consecutive papillary thyroid cancer patients with LN metastases and/or extrathyroidal tumor extension. Initial treatment, performed at the Institut Gustave Roussy between 1987 and 1997, included in all patients a total thyroidectomy with central and ipsilateral en bloc neck dissection followed by radioactive iodine ablation.

Results: Uptake outside the thyroid bed, demonstrating persistent disease, was found on the postablation total body scan (TBS) in 22% of the patients. With a mean follow-up of 8 yr, eight patients (7%) with a normal postablation TBS experienced a recurrence. Ten-year disease-specific survival rate was 99% (confidence interval, 97–100%). Significant risk factors for persistent disease included the numbers of LN metastases (>10) and LN metastases with extracapsular extension (ECE-LN >3), tumor size (>4 cm), and LN metastases location (central). Significant risk factors for recurrent disease included the numbers of LN metastases (>10), ECE-LN (>3), and thyroglobulin level measured 6–12 months after initial treatment after T4 withdrawal.

Conclusion: We highlight an excellent survival rate and suggest risk classifications of persistent and recurrent disease based on the numbers of LN metastases and ECE-LN, LN metastases location, tumor size, and thyroglobulin level.




This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
N. Wada, K. Masudo, H. Nakayama, N. Suganuma, K. Matsuzu, S. Hirakawa, Y. Rino, M. Masuda, and T. Imada
Recommendation for Subclass Evaluation of TNM stage IVA Papillary Thyroid Carcinomas: T4aN1b Patients Are at Risk for Recurrence and Survival
Ann. Surg. Oncol., May 1, 2008; 15(5): 1511 - 1517.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
A. Toniato, I. Boschin, D. Casara, R. Mazzarotto, D. Rubello, and M. Pelizzo
Papillary Thyroid Carcinoma: Factors Influencing Recurrence and Survival
Ann. Surg. Oncol., May 1, 2008; 15(5): 1518 - 1522.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
S. Bardet, E. Malville, J.-P. Rame, E. Babin, G. Samama, D. De Raucourt, J.-J. Michels, Y. Reznik, and M. Henry-Amar
Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma.
Eur. J. Endocrinol., April 1, 2008; 158(4): 551 - 560.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. M. Cerutti, G. Oler, P. Michaluart Jr., R. Delcelo, R. M. Beaty, J. Shoemaker, and G. J. Riggins
Molecular Profiling of Matched Samples Identifies Biomarkers of Papillary Thyroid Carcinoma Lymph Node Metastasis
Cancer Res., August 15, 2007; 67(16): 7885 - 7892.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
R. B T Verkooijen, D. Rietbergen, J. W Smit, J. A Romijn, and M. P M Stokkel
A new functional parameter measured at the time of ablation that can be used to predict differentiated thyroid cancer recurrence during follow-up
Eur. J. Endocrinol., January 1, 2007; 156(1): 41 - 47.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society